A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for Alzheimer’s drugs, Leqembi and Kisunla.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
